Project Grant R01CA297297
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$605K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Lebanon, NH 03756, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $195,766 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Yale University to develop a mechano-transduction platform to enhance chimeric antigen receptor (CAR) T-cell therapies for cancer treatment. The project aims to engineer force-sensitive tools that can measure forces along key immune receptors and integrate them into CARs to improve specificity and safety of CAR T-cell therapies, particularly for solid tumors. This innovative approach...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to enhance the efficacy of non-activated chimeric antigen receptor (CAR) T cell therapies for cancer treatment. The $587,108 award, with a period of performance from August 1, 2024 to July 31, 2029, will be conducted by The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The key objectives of this research...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Dana-Farber Cancer Institute, Inc. (DFCI) to develop a novel adoptive cellular therapy platform using hematopoietic stem cells (HSCs) engineered with chimeric antigen receptor (CAR) technology. The overarching goal is to generate continuously renewing "HSC CAR-NK cell factories" that can provide long-term, cancer-specific immunity. Specifically, the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $627,272 to The Johns Hopkins University to optimize the efficacy of chimeric antigen receptor (CAR) T-cell therapy against pancreatic tumors. The project aims to engineer synthetic cytokine receptors (velocity receptors) to enhance CAR T-cell migration speed and tumor infiltration. The researchers will test the motility and tumor-killing capability of these engineered CAR T-cells in...
This National Science Foundation (NSF) Engineering Program (CFDA 47.041) Project Grant award to Duke University for $574,808 supports research to understand the development of heterogeneity in CAR T-cell populations, which is a critical limitation of CAR T-cell cancer therapies. The research leverages advanced microscopy techniques, dynamic cell tracking, and engineered biomaterial artificial antigen-presenting cells to study how individual T-cell phenotypes emerge from complex, time-varying...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Leland Stanford Junior University (Stanford University) is focused on using a systems biology approach to uncover the molecular mechanisms governing the efficacy of engineered T cell immunotherapies, particularly chimeric antigen receptor (CAR) T cell therapies, for the treatment of large B cell lymphoma (LBCL). The $1,108,391.72 award, spanning January 1, 2025 to December 31, 2027,...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to develop chimeric antigen receptor (CAR) T regulatory cells (Tregs) targeted to amyloid-beta (A-β) as a therapy for Alzheimer's disease (AD). The $704,198 award to Trustees of Dartmouth College aims to enhance the persistence of these CAR Tregs in the central nervous system to rebalance cerebral immunity, promote clearance of A-β, and limit neurodegeneration associated with AD. The...
This Project Grant award of $406,249 from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) was awarded to The Trustees of the University of Pennsylvania on September 18, 2024. The funding supports research to understand the barriers faced by chimeric antigen receptor (CAR) T cell therapy in treating solid tumors. The principal investigator, Dr. Andrew J. Rech, will apply a spatial multi-omic analytical platform to analyze tissue samples from five CAR T...
This $1,271,780 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of Pittsburgh to develop small molecule adaptors for precisely controlling universal chimeric antigen receptor (CAR) T cell therapies. The key objectives are to: Create small molecule adaptors that can target universal CAR T cells to multiple antigens, including on both tumor cells and immunosuppressive cells, to enhance therapeutic specificity....
This federal Project Grant award, provided by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), will support research to dissect the intrinsic variability in engineered T cell immunotherapies. The $330,942 award to Stanford University, beginning September 1, 2024, aims to develop scalable screening methodologies to rapidly assess approved and proposed cellular immunotherapy constructs across a large number of cancer patients. The research will also explore...